Consciousness Disturbances Reported With Clindamycin Versus Cefazolin in Surgical Patients: A Global Pharmacovigilance Analysis Using <scp>VigiBase</scp>
Clindamycin is a common β-lactam substitute for surgical prophylaxis. Whether peri-operative disturbances in consciousness are disproportionately reported with clindamycin in global pharmacovigilance data remains unclear. Using WHO VigiBase (up to January 27, 2025), we performed a de-duplicated case/non-case disproportionality analysis of Individual Case Safety Reports (ICSRs) co-reporting ≥ 1 anesthetic or sedative. Cases were defined by the MedDRA HLT "Disturbances in consciousness NEC." We estimated RORs and aRORs for clindamycin versus cefazolin and other peri-operative comparators (metronidazole, vancomycin, ampicillin), adjusting for age group, sex, and co-reported medications. K-modes clustering characterized co-reporting patterns among clindamycin reports. Sensitivity analyses excluded sepsis-related terms/vasopressors and applied a narrower outcome definition excluding syncope/presyncope. Of 3623 clindamycin ICSRs, 159 (4.4%) included a consciousness-disturbance term. Versus cefazolin, clindamycin generated a disproportionality signal (ROR 2.59, 95% CI 2.07-3.24; aROR 2.23, 95% CI 1.70-2.91), with similar estimates after excluding sepsis/vasopressors (aROR 2.21, 95% CI 1.64-2.98) and syncope/presyncope (aROR 2.11, 95% CI 1.60-2.79). Clustering suggested co-reporting patterns consistent with lidocaine-enriched older-age reports, sedative/anesthetic-enriched younger-age reports, and opioid-enriched reports with high-acuity markers. In VigiBase, disproportionality analyses identified a reporting signal for disturbances in consciousness with clindamycin relative to cefazolin in surgical settings. Because spontaneous reports lack exposure denominators and are susceptible to residual confounding, these findings are hypothesis-generating and do not estimate incidence or comparative risk. Evaluation in data sources with denominators and prospective clinical characterization is warranted.
Authors
- Basile Chrétien (ORCID: https://orcid.org/0000-0002-7483-2489)
- Keita Hiraga (ORCID: https://orcid.org/0000-0002-0134-2956)
- Daigo Tamakoshi
- Tomoyuki Nakamura (ORCID: https://orcid.org/0000-0002-8348-4092)
- Masahisa Katsuno (ORCID: https://orcid.org/0000-0001-9453-9311)
- Hiroshi Morioka (ORCID: https://orcid.org/0000-0003-0299-040X)
- Shigeyuki Matsui (ORCID: https://orcid.org/0000-0003-2983-1919)
- Kazuki Nishida (ORCID: https://orcid.org/0000-0003-0367-8557)
- Yoshitaka Hara (ORCID: https://orcid.org/0000-0002-7433-4359)
Institutions
- Fujita Health University (JP)
- Kyoto University (JP)
- Nagoya City University (JP)
- Nagoya University Hospital (JP)
- Nagoya University (JP)
Publication Details
- Journal
- Clinical and Translational Science
- Published
- 2026-04-01
- DOI
- https://doi.org/10.1111/cts.70534
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- World Health Organization
- Uppsala Monitoring Centre
- Japan Society for the Promotion of Science